niacinamide has been researched along with Asthenia in 10 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Asthenia: Clinical sign or symptom manifested as debility, or lack or loss of strength and energy.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC)." | 7.83 | [Implementation of a nurse-driven educational program improves management of sorafenib's toxicities in hepatocellular carcinoma]. ( Boucher, E; Brunot, A; Crouzet, L; Duval, M; Edeline, J; Guillygomarc'h, A; Laguerre, B; Le Roy, F; Le Sourd, S; Lelievre, N; M'Sadek, A; Ventroux, E, 2016) |
| "Sorafenib is the standard of care for advanced hepatocellular carcinoma (HCC)." | 7.81 | Sorafenib use in elderly patients with hepatocellular carcinoma: caution about use of platelet aggregation inhibitors. ( Boucher, E; Brunot, A; Cattenoz, C; Crouzet, L; Edeline, J; Gédouin, D; Guillygomarc'h, A; Larible, C; Latournerie, M; Le Roy, F; Le Sourd, S, 2015) |
| "Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC)." | 3.83 | [Implementation of a nurse-driven educational program improves management of sorafenib's toxicities in hepatocellular carcinoma]. ( Boucher, E; Brunot, A; Crouzet, L; Duval, M; Edeline, J; Guillygomarc'h, A; Laguerre, B; Le Roy, F; Le Sourd, S; Lelievre, N; M'Sadek, A; Ventroux, E, 2016) |
| "Sorafenib is the standard of care for advanced hepatocellular carcinoma (HCC)." | 3.81 | Sorafenib use in elderly patients with hepatocellular carcinoma: caution about use of platelet aggregation inhibitors. ( Boucher, E; Brunot, A; Cattenoz, C; Crouzet, L; Edeline, J; Gédouin, D; Guillygomarc'h, A; Larible, C; Latournerie, M; Le Roy, F; Le Sourd, S, 2015) |
| "One hundred patients with sleep disorders and asthenic syndrome of various etiology and severity were studied." | 2.90 | [Clinical efficacy of neurometabolic therapy of dissomical disorders in asthenic syndrome]. ( Esipov, AV; Ivolgin, AF; Kalyagin, IE; Karakozov, AG; Katenko, SV; Kazakov, SP; Khritinin, DF; Levchenko, OB; Molodova, AI, 2019) |
| "Angiogenesis does not initiate malignancy but promotes tumor progression and metastasis." | 2.44 | [Oral drugs inhibiting the VEGF pathway]. ( Armand, JP; Mir, O; Ropert, S, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (20.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Esipov, AV | 1 |
| Ivolgin, AF | 1 |
| Khritinin, DF | 1 |
| Katenko, SV | 1 |
| Kazakov, SP | 1 |
| Karakozov, AG | 1 |
| Kalyagin, IE | 1 |
| Levchenko, OB | 1 |
| Molodova, AI | 1 |
| Castellano, D | 1 |
| Capdevila, J | 1 |
| Sastre, J | 1 |
| Alonso, V | 1 |
| Llanos, M | 1 |
| García-Carbonero, R | 1 |
| Manzano Mozo, JL | 1 |
| Sevilla, I | 1 |
| Durán, I | 1 |
| Salazar, R | 1 |
| Derbel Miled, O | 1 |
| Dionne, C | 1 |
| Terret, C | 1 |
| Segura-Ferlay, C | 1 |
| Flechon, A | 1 |
| Neidhart, EM | 1 |
| Negrier, S | 1 |
| Droz, JP | 1 |
| Polunina, AG | 1 |
| Osinovskaia, NA | 1 |
| Gudkova, AN | 1 |
| Gekht, AB | 1 |
| Edeline, J | 2 |
| Crouzet, L | 2 |
| Le Sourd, S | 2 |
| Larible, C | 1 |
| Brunot, A | 2 |
| Le Roy, F | 2 |
| Cattenoz, C | 1 |
| Latournerie, M | 1 |
| Gédouin, D | 1 |
| Guillygomarc'h, A | 2 |
| Boucher, E | 2 |
| M'Sadek, A | 1 |
| Duval, M | 1 |
| Ventroux, E | 1 |
| Lelievre, N | 1 |
| Laguerre, B | 1 |
| Suslina, ZA | 1 |
| Klocheva, EG | 1 |
| Piradov, MA | 1 |
| Rumiantseva, SA | 1 |
| Romantsov, MG | 1 |
| Kovalenko, AL | 1 |
| Ropert, S | 1 |
| Mir, O | 1 |
| Armand, JP | 1 |
| Pietranera, P | 1 |
| Chouinard, C | 1 |
1 review available for niacinamide and Asthenia
| Article | Year |
|---|---|
[Oral drugs inhibiting the VEGF pathway].
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Asthenia; Axitinib; Benzenesulfonates; Human | 2007 |
2 trials available for niacinamide and Asthenia
| Article | Year |
|---|---|
[Clinical efficacy of neurometabolic therapy of dissomical disorders in asthenic syndrome].
Topics: Administration, Oral; Antioxidants; Asthenia; Drug Combinations; Flavin Mononucleotide; Humans; Inos | 2019 |
Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: a phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asth | 2013 |
7 other studies available for niacinamide and Asthenia
| Article | Year |
|---|---|
Sorafenib and sunitinib for elderly patients with renal cell carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Asthenia; Carcinoma, Renal Cell; Disease-Free Surviv | 2013 |
[Influence of cytoflavin on symptoms of asthenia, emotional disorders and autonomic regulation in patients with organic asthenic disorder].
Topics: Adult; Asthenia; Autonomic Nervous System; Drug Combinations; Emotions; Female; Flavin Mononucleotid | 2014 |
Sorafenib use in elderly patients with hepatocellular carcinoma: caution about use of platelet aggregation inhibitors.
Topics: Aged; Aged, 80 and over; Aging; Antineoplastic Agents; Asthenia; Carcinoma, Hepatocellular; Comorbid | 2015 |
[Implementation of a nurse-driven educational program improves management of sorafenib's toxicities in hepatocellular carcinoma].
Topics: Administration, Oral; Aged; Antineoplastic Agents; Asthenia; Carcinoma, Hepatocellular; Diarrhea; Fe | 2016 |
[Efficacy of cytoflavin in the treatment of chronic cerebral ischemia].
Topics: Asthenia; Brain Ischemia; Chronic Disease; Drug Combinations; Flavin Mononucleotide; Humans; Inosine | 2010 |
[Therapeutic value of an association of phospholipids and adrenal cortex in hepatology].
Topics: Adolescent; Adrenal Cortex Hormones; Adrenal Glands; Adult; Aged; Asthenia; Biliary Tract Diseases; | 1971 |
[Asthenia in children].
Topics: Adolescent; Asthenia; Child; Child, Preschool; Fructosephosphates; Humans; Lysine; Niacinamide; Pare | 1973 |